Clinical Trials List
Protocol NumberA20-101
NCT Number(ClinicalTrials.gov Identfier)NCT04638439
Active
2020-07-01 - 2024-12-31
Phase I
Not yet recruiting1
Recruiting4
ICD-10B18.0
Chronic viral hepatitis B with delta-agent
ICD-9070.33
Viral hepatitis B without mention of hepatic coma, chronic, with hepatitis delta
A Phase Ib, Open Label Study to Assess the Safety and Efficacy of Sequential Administration of P1101 and Anti-PD1 in Interferon-Naive Adults With Chronic Hepatitis B or D Infection
-
Trial Applicant
-
Sponsor
PharmaEssentia
-
Trial scale
Taiwan Multiple Center
-
Update
2026/02/01
Investigators and Locations
Co-Principal Investigator
- I-Cheng Lee Digestive System Department
- Chien-Wei Su Digestive System Department
The Actual Total Number of Participants Enrolled
0 Recruiting
Co-Principal Investigator
- Yi-Cheng Chen Digestive System Department
- Chao-Wei Hsu Digestive System Department
The Actual Total Number of Participants Enrolled
0 Recruiting
Co-Principal Investigator
- CHANG-HAO YANG Division of Ophthalmology
- Chun-Jen Liu Digestive System Department
- 楊宏志 Digestive System Department
The Actual Total Number of Participants Enrolled
0 Recruiting
Co-Principal Investigator
- 黃奕文 Digestive System Department
- 劉正典 Digestive System Department
- Tiong Cheng Digestive System Department
- Chun-Chao Chang Digestive System Department
The Actual Total Number of Participants Enrolled
0 Recruiting
Co-Principal Investigator
The Actual Total Number of Participants Enrolled
0 Not yet recruiting
Condition/Disease
Chronic Hepatitis B Infection/Chronic Hepatitis D Infection
Objectives
Primary objective:
To evaluate the safety and tolerability of sequential administration of P1101 and anti-PD1 in patient with chronic hepatitis B or D infection
Secondary objectives:
To explore HBsAg loss and kinetics during the study period
To assess the anti-viral effect during the study period
To evaluate the rate of ALT normalization
There are 20 scheduled visits (screening, treatment weeks & follow-up weeks) for patients with > 0.5 log10 decline in HBsAg at TW12, which include screening visit, TW0 (baseline), TW2, TW4, TW6, TW8, TW10, TW12, TW13, TW15, TW17, TW19, TW21, TW23 (EOT), FW4, FW8, FW12, FW16, FW20 and FW24.
There are 22 scheduled visits for patients with ≤ 0.5 log10 decline in HBsAg at TW12. These visits include screening visit, TW0 (baseline), TW2, TW4, TW6, TW8, TW10, TW12, TW13, TW16, TW17, TW19, TW21, TW23, TW25, TW27 (EOT), FW4, FW8, FW12, FW16, FW20 and FW24.
Test Drug
P1101 (Ropeginterferon alfa-2b)
Active Ingredient
Ropeginterferon alfa-2b
Dosage Form
Pre-filled syringe
Dosage
500
Endpoints
Primary Outcome Measures :
Safety: AE/SAE [ Time Frame: Through study Follow-up Week 24 (up to 330 or 358 days) ]
Number of patients with adverse events, including SAEs
Safety: clinically significant abnormalities [ Time Frame: Through study Follow-up Week 24 (up to 330 or 358 days) ]
Number of patients with clinically significant abnormalities, including vital sign, physical examination, electrocardiogram (ECG) and laboratory data
Secondary Outcome Measures :
Subjects with HBsAg loss [ Time Frame: Treatment Week 12, Treatment Week 23 or 27, Follow-up Week 12 and Follow-up Week 24 ]
The percentage of subjects with HBsAg loss at treatment week 12, 23/27 and follow up week 12, 24 in the treatment group
Subjects with HBsAg reduction from baseline [ Time Frame: Treatment Week 12, Treatment Week 23 or 27, Follow-up Week 12 and Follow-up Week 24 ]
The percentage of subjects with HBsAg reduction from baseline at treatment week 12, 23/27 and follow up week 12, 24 in the treatment group
Subjects with HBsAg seroconversion [ Time Frame: Treatment Week 12, Treatment Week 23 or 27, Follow-up Week 12 and Follow-up Week 24 ]
The percentage of subjects with HBsAg seroconversion at treatment week 12, 23/27 and follow up week 12, 24 in the treatment group
Subjects with undetectable HBV DNA [ Time Frame: Treatment Week 12, Treatment Week 23 or 27, Follow-up Week 12 and Follow-up Week 24 ]
The percentage of subjects with undetectable HBV DNA at treatment week 12, 23/27 and follow up week 12, 24 in the treatment group
Subjects with ≥ 2 log10 decline from baseline in HDV RNA [ Time Frame: Treatment Week 12, Treatment Week 23 or 27, Follow-up Week 12 and Follow-up Week 24 ]
The percentage of subjects with ≥ 2 log10 decline from baseline in HDV RNA at treatment week 12, 23/27 and follow up week 12, 24 in the treatment group
Subjects with undetectable HDV RNA [ Time Frame: Treatment Week 12, Treatment Week 23 or 27, Follow-up Week 12 and Follow-up Week 24 ]
The percentage of subjects with undetectable HDV RNA at treatment week 12, 23/27 and follow up week 12, 24 in the treatment group
Subjects with ALT normalization [ Time Frame: Treatment Week 12, Treatment Week 23 or 27, Follow-up Week 12 and Follow-up Week 24 ]
The percentage of subjects with ALT normalization at treatment week 12, 23/27 and follow up week 12, 24 in the treatment group
Safety: AE/SAE [ Time Frame: Through study Follow-up Week 24 (up to 330 or 358 days) ]
Number of patients with adverse events, including SAEs
Safety: clinically significant abnormalities [ Time Frame: Through study Follow-up Week 24 (up to 330 or 358 days) ]
Number of patients with clinically significant abnormalities, including vital sign, physical examination, electrocardiogram (ECG) and laboratory data
Secondary Outcome Measures :
Subjects with HBsAg loss [ Time Frame: Treatment Week 12, Treatment Week 23 or 27, Follow-up Week 12 and Follow-up Week 24 ]
The percentage of subjects with HBsAg loss at treatment week 12, 23/27 and follow up week 12, 24 in the treatment group
Subjects with HBsAg reduction from baseline [ Time Frame: Treatment Week 12, Treatment Week 23 or 27, Follow-up Week 12 and Follow-up Week 24 ]
The percentage of subjects with HBsAg reduction from baseline at treatment week 12, 23/27 and follow up week 12, 24 in the treatment group
Subjects with HBsAg seroconversion [ Time Frame: Treatment Week 12, Treatment Week 23 or 27, Follow-up Week 12 and Follow-up Week 24 ]
The percentage of subjects with HBsAg seroconversion at treatment week 12, 23/27 and follow up week 12, 24 in the treatment group
Subjects with undetectable HBV DNA [ Time Frame: Treatment Week 12, Treatment Week 23 or 27, Follow-up Week 12 and Follow-up Week 24 ]
The percentage of subjects with undetectable HBV DNA at treatment week 12, 23/27 and follow up week 12, 24 in the treatment group
Subjects with ≥ 2 log10 decline from baseline in HDV RNA [ Time Frame: Treatment Week 12, Treatment Week 23 or 27, Follow-up Week 12 and Follow-up Week 24 ]
The percentage of subjects with ≥ 2 log10 decline from baseline in HDV RNA at treatment week 12, 23/27 and follow up week 12, 24 in the treatment group
Subjects with undetectable HDV RNA [ Time Frame: Treatment Week 12, Treatment Week 23 or 27, Follow-up Week 12 and Follow-up Week 24 ]
The percentage of subjects with undetectable HDV RNA at treatment week 12, 23/27 and follow up week 12, 24 in the treatment group
Subjects with ALT normalization [ Time Frame: Treatment Week 12, Treatment Week 23 or 27, Follow-up Week 12 and Follow-up Week 24 ]
The percentage of subjects with ALT normalization at treatment week 12, 23/27 and follow up week 12, 24 in the treatment group
Inclution Criteria
Inclusion Criteria:
Positive for HBsAg for at least 6 months, either HBeAg (+) or HBeAg (-), and ALT ≥ULN to ≤ 10X ULN at screening;
Interferon naïve;
Quantitative HBsAg Level < 1,500 IU/mL at screening; Undetectable HBV DNA (either under NUC treatment or not)
Adults ≥20 years of age; patients who are over 70 years of age must be in generally good health depending upon the Investigator's judgment;
Laboratory test results before study entry: WBC ≥ 3,000/mm3; ANC ≥ 1,500/mm3; Platelet ≥ 90,000/mm3; Hemoglobin ≥ 10g/dL; e-GFR ≥ 60mL/min;
ECG without clinically significant abnormalities before study entry;
Be able to attend all scheduled visits and to comply with all study procedures;
Patients with anti-HDV (+) can be enrolled;
Patients with fibrosis stage < F4 can be enrolled;
Willing to provide written informed consent;
Positive for HBsAg for at least 6 months, either HBeAg (+) or HBeAg (-), and ALT ≥ULN to ≤ 10X ULN at screening;
Interferon naïve;
Quantitative HBsAg Level < 1,500 IU/mL at screening; Undetectable HBV DNA (either under NUC treatment or not)
Adults ≥20 years of age; patients who are over 70 years of age must be in generally good health depending upon the Investigator's judgment;
Laboratory test results before study entry: WBC ≥ 3,000/mm3; ANC ≥ 1,500/mm3; Platelet ≥ 90,000/mm3; Hemoglobin ≥ 10g/dL; e-GFR ≥ 60mL/min;
ECG without clinically significant abnormalities before study entry;
Be able to attend all scheduled visits and to comply with all study procedures;
Patients with anti-HDV (+) can be enrolled;
Patients with fibrosis stage < F4 can be enrolled;
Willing to provide written informed consent;
Exclusion Criteria
Exclusion Criteria:
Clinically significant illness or surgery that might interfere with study participation;
Clinically significant vital sign abnormalities or fever [body temperature >38℃]);
History of significant alcohol or drug abuse within 6 months prior to the screening visit (alcohol consumption of more than 14 units of alcohol per week [1 Unit = 150 mL of wine, 360 mL of beer, or 45 mL of 40% alcohol]) or refusal to abstain from alcohol or illicit drugs throughout the study;
Any history or presence of poorly controlled or clinically significant medical conditions that are not suitable to receive interferon-based treatment, at the discretion of the investigator: major psychiatric (including but not limited to those with severe depression, severe bi-polar disorder, schizophrenia, suicidal ideation or history of suicidal attempt), neurological, cardiovascular (i.e. uncontrolled hypertension, congestive heart failure (≥ NYHA class 2), serious cardiac arrhythmia, significant coronary artery stenosis, unstable angina) or recent stroke or myocardial infarction), pulmonary, hematologic, immunologic, autoimmune diseases, thyroid or other endocrine diseases, metabolic (e.g. diabetes mellitus with HbA1C > 8.0%) or other uncontrolled systemic disease, coagulation disorders or blood dyscrasias;
Pregnant patient, female patient or the spouse of male patient, with child-bearing potential who is unwilling or unable to practice adequate contraception, defined as vasectomy in men, tubal ligation in women, or use of condoms and spermicides, or birth control pills, or intrauterine devices throughout the study;
History of severe allergic or hypersensitivity reactions, e.g. hypersensitivity to the active substance or to any of the excipients of Ropeginterferon alfa-2b (P1101), bronchospasm, angioedema, asthma, or anaphylaxis;
Therapy with any systemic anti-viral treatment, anti-neoplastic, or immunomodulatory treatment (including supraphysiologic doses of steroids and radiation) within 1 month (3 months for those with long elimination half-lives) prior to the first dose of study drug;
A depot injection or an implant of any drug within 3 months prior to administration of study medication, other than contraception or hyaluronic acid injections in joints for osteoarthritis;
Body organ transplant or taking immunosuppressant;
Use investigational drug of other clinical trials within 4 weeks prior to the first dose of the study drug;
History of malignancy diagnosed or treated within 5 years prior to screening (except for localized treatment of squamous or non-invasive basal cell skin cancers; cervical carcinoma in situ);
History of opportunistic infection (e.g., invasive candidiasis or pneumocystis pneumonia);
Serious localized infection (e.g., cellulitis, abscess) or systemic and life-threatening infection (e.g., septicemia) within 3 months prior to screening;
Clinically significant medical conditions known to interfere absorption, distribution, metabolism or excretion of the study drugs;
Decompensated liver disease, which includes but not limited to the following: total bilirubin≥2 mg/dL (except in Gilbert syndrome), direct bilirubin ≥2X ULN, albumin level < 3.5 g/dL, INR ≥1.5; clinical evidence of ascites, liver decompensation, hepatic encephalopathy, oesophageal varices or cirrhosis as identified by ultrasound or any other examination before study entry;
Significant steatohepatitis by ultrasound or other examination at the discretion of investigator;
Other form of significant chronic liver diseases, except those mentioned above (e.g. HBV, HDV);
Significant or major fundoscopic findings at screening including but not limited to retinal exudates, hemorrhage, detachment, neovascularization, papilledema, optic atrophy, microaneurysms and macular changes;
Positive for anti-HIV or anti-HCV;
Prior therapy with anti-PD-1, anti-PD-L1, anti-PD-L2, anti-CD137, anti-CTLA-4 antibody, or any other antibody or drug specifically targeting T-cell co-stimulation or immune checkpoint pathway;
Any contraindication to receiving anti-PD-1 antibody (e.g. active or a history of life-threatening autoimmune conditions, corticosteroids treatment required) or hypersensitivity to the constituents of anti-PD-1 antibody;
Patients under monotherapy by telbivudine or any other combination therapy with telbivudine.
Clinically significant illness or surgery that might interfere with study participation;
Clinically significant vital sign abnormalities or fever [body temperature >38℃]);
History of significant alcohol or drug abuse within 6 months prior to the screening visit (alcohol consumption of more than 14 units of alcohol per week [1 Unit = 150 mL of wine, 360 mL of beer, or 45 mL of 40% alcohol]) or refusal to abstain from alcohol or illicit drugs throughout the study;
Any history or presence of poorly controlled or clinically significant medical conditions that are not suitable to receive interferon-based treatment, at the discretion of the investigator: major psychiatric (including but not limited to those with severe depression, severe bi-polar disorder, schizophrenia, suicidal ideation or history of suicidal attempt), neurological, cardiovascular (i.e. uncontrolled hypertension, congestive heart failure (≥ NYHA class 2), serious cardiac arrhythmia, significant coronary artery stenosis, unstable angina) or recent stroke or myocardial infarction), pulmonary, hematologic, immunologic, autoimmune diseases, thyroid or other endocrine diseases, metabolic (e.g. diabetes mellitus with HbA1C > 8.0%) or other uncontrolled systemic disease, coagulation disorders or blood dyscrasias;
Pregnant patient, female patient or the spouse of male patient, with child-bearing potential who is unwilling or unable to practice adequate contraception, defined as vasectomy in men, tubal ligation in women, or use of condoms and spermicides, or birth control pills, or intrauterine devices throughout the study;
History of severe allergic or hypersensitivity reactions, e.g. hypersensitivity to the active substance or to any of the excipients of Ropeginterferon alfa-2b (P1101), bronchospasm, angioedema, asthma, or anaphylaxis;
Therapy with any systemic anti-viral treatment, anti-neoplastic, or immunomodulatory treatment (including supraphysiologic doses of steroids and radiation) within 1 month (3 months for those with long elimination half-lives) prior to the first dose of study drug;
A depot injection or an implant of any drug within 3 months prior to administration of study medication, other than contraception or hyaluronic acid injections in joints for osteoarthritis;
Body organ transplant or taking immunosuppressant;
Use investigational drug of other clinical trials within 4 weeks prior to the first dose of the study drug;
History of malignancy diagnosed or treated within 5 years prior to screening (except for localized treatment of squamous or non-invasive basal cell skin cancers; cervical carcinoma in situ);
History of opportunistic infection (e.g., invasive candidiasis or pneumocystis pneumonia);
Serious localized infection (e.g., cellulitis, abscess) or systemic and life-threatening infection (e.g., septicemia) within 3 months prior to screening;
Clinically significant medical conditions known to interfere absorption, distribution, metabolism or excretion of the study drugs;
Decompensated liver disease, which includes but not limited to the following: total bilirubin≥2 mg/dL (except in Gilbert syndrome), direct bilirubin ≥2X ULN, albumin level < 3.5 g/dL, INR ≥1.5; clinical evidence of ascites, liver decompensation, hepatic encephalopathy, oesophageal varices or cirrhosis as identified by ultrasound or any other examination before study entry;
Significant steatohepatitis by ultrasound or other examination at the discretion of investigator;
Other form of significant chronic liver diseases, except those mentioned above (e.g. HBV, HDV);
Significant or major fundoscopic findings at screening including but not limited to retinal exudates, hemorrhage, detachment, neovascularization, papilledema, optic atrophy, microaneurysms and macular changes;
Positive for anti-HIV or anti-HCV;
Prior therapy with anti-PD-1, anti-PD-L1, anti-PD-L2, anti-CD137, anti-CTLA-4 antibody, or any other antibody or drug specifically targeting T-cell co-stimulation or immune checkpoint pathway;
Any contraindication to receiving anti-PD-1 antibody (e.g. active or a history of life-threatening autoimmune conditions, corticosteroids treatment required) or hypersensitivity to the constituents of anti-PD-1 antibody;
Patients under monotherapy by telbivudine or any other combination therapy with telbivudine.
The Estimated Number of Participants
-
Taiwan
20 participants
-
Global
20 participants
